CoChat

Diagnosis and Treatment of Patients with Severe Alzheimer’s Disease

Voisin, Thierry, Vellas, Bruno · 2009 · Drugs & Aging

The DOI matches its Crossref record; 55 of the 57 references it cites were found in a registry or an index.

Abstract

In contrast with the earlier stages and, in particular, the predementia stage, of Alzheimer's disease (AD), severe dementia is often neglected. However, the advanced stages of dementia are just as important as the earlier stages because of their frequency, their impact on the lives of patients and their caregivers, and their economic consequences. All patients with moderately severe to severe dementia must be evaluated for cognitive, functional, psychological and behavioural symptoms. Thorough and regular evaluation of patients in the advanced stages of the disease has the following objectives: improving patients' quality of life by encouraging use of their remaining capacities; setting up or modifying a care plan; playing a role in the follow-up of measures instituted; and documenting the natural history of the disease. Therapeutic trials with cholinesterase inhibitors and memantine have been conducted in patients with severe stages of AD. As a consequence, memantine has been approved by numerous drug agencies and donepezil has been approved by the US FDA for use in severe stages of the disease. However, it is important to note that at this stage of AD, and perhaps more than in any other, management must be global and multidisciplinary because of the expression of the disease, its complications and intercurrent disorders. Indeed, thorough knowledge by health professionals of the expression of all disease disorders and intercurrent disorders, and of their significance during…

Overview

Integrity signals

Registry

Crossref · 10.2165/0002512-200926020-00005

Cites

55 of 55 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 55 references

Research works printed but not linked: 7

  1. Eastwood, 1994, Int Psychiatry Today, 4, 8
  2. Gillette-Guyonnet, 2003, J Nutr Health Ageing, 7, 91
  3. Saxton, 1990, J Consult Clin Psychol, 3, 198
  4. Warshaw, 1997, Alzheimer Dis Assoc Disord, 11, 66
  5. Vellas, 2005, J Nutr Health Aging, 9, 330
  6. 2003, J Nutr Health Aging, 7, 304
  7. Ballard, 2006, Cochrane Database Syst Rev, &NA;, CD003476

Cited by

See all 89

Metadata

Authors
Voisin, T., & Vellas, B.
Affiliations
Inserm (FR)
Corresponding author
Vellas, Bruno
Venue
Drugs & Aging
Published
2009
Volume
26
Issue
2
Pages
135-144
ISSN
1170-229X (ISSN-L)
OpenAlex
W2092173737
Cited by
89
References
57
Citations by year
2025: 4 · 2024: 5 · 2023: 8 · 2022: 8 · 2021: 6 · 2020: 6 · 2019: 7 · 2018: 3 · 2017: 6 · 2016: 3 · 2015: 4 · 2014: 6 · 2013: 6 · 2012: 5
FWCI
3.44
Type
journal article
Language
en
Open access
closed
Locations
  • Drugs & Aging (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
Keywords
severe Alzheimer's disease, advanced dementia, cholinesterase inhibitors, memantine, donepezil, multidisciplinary care, behavioural symptoms, functional assessment, quality of life, natural history of dementia, dementia management
MeSH terms
Alzheimer Disease, Clinical Trials as Topic, Humans, Quality of Life, Caregivers

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Diagnosis and Treatment of Patients with Severe Alzheimer’s Disease. https://app.cochat.ai/papers/10.2165/0002512-200926020-00005
The paper
Voisin, T., & Vellas, B. (2009). Diagnosis and Treatment of Patients with Severe Alzheimer’s Disease. Drugs & Aging. https://doi.org/10.2165/0002512-200926020-00005

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.